RAC1 and hepatocellular carcinoma: In this study, we identified MG53 as a novel RAC1 inhibitor and it suppressed HCC progression via its direct interaction with RAC1 and induced K48-linked poly-ubiquitination of RAC1 at Lys5 residue, which further led to the inhibition of RAC1-MAPK signaling.